RIBOPRO, a leading biotechnology company dedicated to supporting biotech and biopharma in the co-creation of innovative mRNA medicines based on proprietary mRNA technologies and high-quality mRNA/LNP manufacturing, proudly announces the successful completion of a €1.9 million Convertible Loan Agreement (CLA) that marks a significant milestone in its growth trajectory.
Following almost two years of construction, the Curie building at Pivot Park is nearly ready to welcome its first tenants. This compact 9-storey building, offering plenty of light and easy adaptation to tenants’ needs, is designed based on collaboration, with a central meeting hub and office spaces, customised laboratories, and communal facilities.
Press release: Pivot Park grows by over 25% with the completion of the Grizzly project
Today, contractor Dura Vermeer Bouw Zuid completes the Grizzly project after nearly 2 years of construction, delivering it to Pivot Park. The 9-story building, named after Nobel laureate Marie Curie, will house offices, laboratories, and shared facilities. With the completion of this sustainable building, Pivot Park adds 11,000 square meters to its successful campus, marking an expansion of over 25 percent.
Ardena and ELDICO Scientific have teamed up, granting Ardena access to ELDICO’s cutting-edge electron diffractometer, the ELDICO ED-1.
Ardena and ELDICO Scientific announce collaboration agreement
Ardena and ELDICO Scientific have teamed up, granting Ardena access to ELDICO’s cutting-edge electron diffractometer, the ELDICO ED-1.
SOTIO Enters Licensing Agreement With Synaffix to Expand ADC Pipeline
SOTIO enters agreement with Synaffix. This remarkable agreement provides SOTIO Bio access to ADC technologies, GlycoConnect™, HydraSpace™, and toxSYN™ linker-payloads to expand their #ADC pipeline.
Pharma cluster wraps up 100-Year celebration with successful Pharma Future Run
Pivot Park hosted the Pharma Future Walk last Sunday, concluding a year-long celebration of Oss’s 100-year pharmaceutical history. The starting and finishing lines were right here at Pivot Park, with a unique route through Oss’s pharmaceutical companies.
Leaders in Life Sciences – #22 Nettie Buitelaar
In the Leaders of Life Sciences Podcast, André van de Sande talks to leaders of now and soon in the life sciences sector. We believe that there needs to be more spoken by people in the sector about themselves but also about their work. That starts with the leaders of today who are questioned about their careers and motivations. These are leaders working in the broadest corners of the industry, but they all have one thing in common: our guests all have a mission to contribute to improving health worldwide. In episode 22, our guest is Nettie Buitelaar, CEO of Biotech Booster.
Leaders in Life Sciences – #21 Paul Peter Tak
In the Leaders of Life Sciences Podcast, André van de Sande talks to leaders of now and soon in the life sciences sector. We believe that there needs to be more spoken by people in the sector about themselves but also about their work. That starts with the leaders of today who are questioned about their careers and motivations. These are leaders working in the broadest corners of the industry, but they all have one thing in common: our guests all have a mission to contribute to improving health worldwide. In episode 21, our guest is Paul Peter Tak, CEO of Candel Therapeutics.
Pivot Park opens its doors with the unveiling of the Walk of Fame
Always wanted to know what goes on behind closed doors at Pivot Park? From today on, you get the opportunity to learn more about the biopharmaceutical park and its residents. Follow the Walk of Fame at Pivot Park: a route of photos, videos, and audio which tells you in an interactive way the stories the companies at Pivot Park have to tell you.
Expansion of the Management of Nelisca Life Science Accounting Firm
Mr. Sander Verbaarschot has joined the management team of Nelisca. This is a new step in an existing collaboration. The formalization aligns with the ambitions to grow and meet the increasing demand from the life science market for fiscal, financial, and administrative advice.
Synaffix entered into licensing agreement with ABL Bio Inc.
Synaffix B.V., a Lonza subsidiary, and ABL Bio, Inc., have joined forces to develop innovative bispecific antibody-drug conjugates (ADCs). Synaffix will handle component manufacturing, receiving upfront payment, milestones, and royalties, while ABL Bio will lead research, development, and commercialization.
This partnership aims to improve cancer cell targeting and therapeutic safety by creating ADCs that bind to two antigens. Lonza, recently acquiring Synaffix, is poised to support clinical production.
or call
Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.